At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Carfilzomibdrug
Likely dose
Carfilzomib 10 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
In Brief
A Phase 2 clinical trial evaluating Carfilzomib for Multiple Myeloma and Renal Insufficiency. Completed, enrolled 50 participants across 5 sites.
Detailed Summary
The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Renal Insufficiency
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartNov 2008
Primary CompletionNov 2012
TodayJul 2026
First PostedJul 24, 2008
Enrollment StartNov 1, 2008
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 17.9 years ago
Interventions
Carfilzomibdrug
Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.